The role of statin therapy in the prevention of atrial fibrillation: A meta-analysis of randomized controlled trials

British Journal of Clinical Pharmacology

Volumn 74, Issue 5, 2012, Pages 744-756

  Fang, Wen Tong ^a   Li, Hong Jian ^b   Zhang, Haibo ^a   Jiang, Su ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Atrial fibrillation; Meta analysis; Statins

Indexed keywords

AMIODARONE; ATORVASTATIN; CAPTOPRIL; DIGOXIN; DILTIAZEM; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOPULMONARY BYPASS; CARDIOVASCULAR RISK; CARDIOVERSION; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY SURGERY; DRUG EFFICACY; DRUG USE; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACEMAKER; HEART FAILURE; HEART SURGERY; HUMAN; INCIDENCE; META ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SENSITIVITY ANALYSIS;

ATRIAL FIBRILLATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK; SECONDARY PREVENTION;

EID: 84863469931     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04258.x     Document Type: Article

References (50)

1. Moe GK, Abildskov JA. Atrial fibrillation as self-sustaining arrhythmia independent of focal discharge. Am Heart J 1959; 58: 59-70.
2. Chen PS, Athill CA, Wu TJ, Ikeda T, Ong JJ, Karagueuzian HS. Mechanisms of atrial fibrillation and flutter and implications for management. Am J Cardiol 1999; 84: 125R-30R.
3. Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A, Calkins H, Connolly SJ, Curtis AB, Darbar D, Ellinor PT, Go AS, Goldschlager NF, Heckbert SR, Jalife J, Kerr CR, Levy D, Lloyd-Jones DM, Massie BM, Nattel S, Olgin JE, Packer DL, Po SS, Tsang TS, Van Wagoner DR, Waldo AL, Wyse DG. Prevention of Atrial Fibrillation: report from a National Heart, Lung, and Blood Institute Workshop. Circulation 2009; 119: 606-18.
4. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Heuzey Le JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S. ACC/AHA/ESC 2006 guidelines for the management of patients with AF. J Am Coll Cardiol 2006; 48: 854-906.
5. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TSM. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-25.
6. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK. Inflammation as a risk factor for AF. Circulation 2003; 108: 3006-10.
7. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of AF: a systematic review of the published data. J Am Coll Cardiol 2007; 50: 2021-8.
8. Fauchier L, Pierre B, Labriolle A, Grimard C, Zannad N, Babuty D. Antiarrhythmic Effect of Statin Therapy and Atrial Fibrillation: a Meta-Analysis of Randomized Controlled Trials. J Am Coll Cardiol 2008; 51: 828-35.
9. Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, Williard A. Atrial Fibrillation at Baseline and During Follow-Up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol 2009; 54: 2023-31.
10. Almroth H, Hoglund N, Boman K, Englund A, Jensen S, Kjellman B, Tornvall P, Rosenqvist M. Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. Eur Heart J 2009; 30: 827-33.
11. Patti G, Chello M, Candura D, Pasceri V, Ambrosio AD, Covino E, Sciascio GD. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia after cardiac surgery) study. Circulation 2006; 114: 1455-61.
12. Caorsi C, Pineda F, Munoz C. Pravastatin immunomodulates IL-6 and C-reactive protein, but not IL-1 and TNF-a, in cardio-pulmonary bypass. Eur Cytokine Netw 2008; 19: 99-103.
13. Chello M, Patti G, Candura D, Mastrobuoni S, Sciascio GD, Agrò F, Carassiti M, Covino E. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med 2006; 34: 660-7.
14. Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2005; 150: 1064e7-e12.
15. Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG, Latini R, Nicolosi GL, Porcu M, Cosmi F, Stefanelli S, Tognoni G, Tavazzi L. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J 2009; 30: 2327-36.
16. Mannacio VA, Iorio D, De Amicis V, Di Lello F, Musumeci F. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial. J Thorac Cardiovasc Surg 2008; 136: 1541-8.
17. Schwartz GG, Olsson AG, Chaitman B, Goldberger J, Szarek M, Sasiela WJ. Effect of intensive statin treatment on the occurrence of atrial fibrillation after acute coronary syndrome: an analysis of the MIRACL trial. Circulation 2004; 110 (Suppl.): S740.
18. Ozaydin M, Varol E, Aslan SM, Kucuktepe Z, Dogan A, Ozturk M, Altinbas A. Effect of Atorvastatin on the Recurrence Rates of Atrial Fibrillation After Electrical Cardioversion. Am J Cardiol 2006; 97: 1490-3.
19. Qian YJ, Xiao XJ, Yuan HS, Tang H, Shao HZ, Wei DM. Combination pharmacological cardioversion of permanent atrial fibrillation in post-prosthetic mitral valve replacement outpatients: a novel approach for the treatment of atrial fibrillation. J Int Med Res 2008; 36: 537-43.
20. Song YB, On YK, Kim JH, Shin DH, Kim JS, Sung J, Lee SH, Kim WS, Lee YT. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am Heart J 2008; 156: 373e9-16.
21. Spadaccio C, Pollari F, Casacalenda A, Alfano G, Genovese J, Covino E, Chello M. Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery: a randomized control study. J Cardiovasc Pharmacol 2010; 55: 30-8.
22. Negi S, Shukrullah I, Veladar E, Bloom HL, Jones DP, Dudley SC. Statin therapy for prevention of Atrial Fibrillation trial (STOP AF trial). Eur Heart J 2010; 31 (Suppl. 1): 885-6.
23. Sun YF, Mei YQ, Ji Q, Wang XS, Feng J, Cai JZ, Zhou YX, Xie SL. Effect of atorvastatin on postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting. Chinese Med J 2009; 89: 2988-91.
24. Tamayo E, Alvarez FJ, Alonso O, Bustamante R, Castrodeza J, Soria S, Lajo C. Effects of simvastatin on systemic inflammatory responses after cardiopulmonary bypass. J Cardiovasc Surg (Torino) 2009; 50: 687-94.
25. Tsai CT, Lai LP, Hwang JJ, Wang YC, Chiang FT, Lin JL. Atorvastatin prevents atrial fibrillation in patients with bradyarrhythmias and implantation of an atrial-based or dual-chamber pacemaker: a prospective randomized trial. Am Heart J 2008; 156: 65-70.
26. Tveit A, Grundtvig M, Gundersen T, Vanberg P, Semb AG, Holt E, Gullestad L. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2004; 93: 780-2.
27. Macfarlane PW, Norrie J. The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland Coronary Prevention Study. J Electrocardiol 2007; 40: 101-9.
28. Xia W, Yin Z, Li J, Song Y, Qu X. Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. Pacing Clin Electrophysiol 2009; 32: 1562-6.
29. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c869-97.
30. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
31. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48.
32. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
33. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
34. García-Fernández A, Marin F, Mainar L, Roldán V, Martínez JG. Effect of statins on preventing recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006; 98: 1299-300.
35. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, Barash PG, Hsu PH, Mangano DT. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004; 291: 1720-9.
36. Fauchier L. Statins and atrial fibrillation - developments and advances. Eur Cardiol 2008; 4: 93-5.
37. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423-7.
38. Naji F, Suran D, Kanic V, Vokac D, Sabovic M. Statins and amiodarone improve freedom from recurrence of atrial fibrillation after successful cardioversion. Med Sci Monit 2009; 15: CR494-8.
39. Humphries KH, Lee M, Sheldon R, Ramanathan K, Dorian P, Green M, Kerr CR. Statin use and recurrence of atrial fibrillation after successful cardioversion. Am Heart J 2007; 154: 908-13.
40. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92: 1343-5.
41. Bhardwaj A, Sood NA, Kluger J, Coleman CI. Lack of effect of statins on maintenance of normal sinus rhythm following electrical cardioversion of persistent atrial fibrillation. Int J Clin Pract 2010; 64: 1116-20.
42. Aranki SF, Shaw DP, Adams DH, Rizzo RJ, Couper GS, VanderVliet M, Collins JJ Jr, Cohn LH, Burstin HR. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation 1996; 94: 390-7.
43. Marin F, Pascual DA, Roldan V, Arribas JM, Ahumada M, Tornel PL, Oliver C, Gómez-Plana J, Lip GY, Valdés M. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 2006; 97: 55-60.
44. Dotani MI, Elnicki DM, Jain AC, Gibson CM. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 2000; 86: 1128-30.
45. Liakopoulos OJ, Choi YH, Kuhn EW, Wittwer T, Borys M, Madershahian N, Wassme G, Wahlers T. Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review. J Thorac Cardiovasc Surg 2009; 138: 678 - 86.
46. Liakopoulos OJ, Choi YH, Haldenwang PL, Strauch J, Wittwer T, Dörge H, Stamm C, Wassmer G, Wahlers T. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30000 patients. Eur Heart J 2008; 29: 1548-59.
47. Takagi H, Umemoto T. Effect of Preoperative Statin Therapy on Postoperative Atrial Fibrillation in Cardiac Surgery. Circ J 2010; 74: 2788-9.
48. Adabag AS, Nelson DB, Bloomfield HE. Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure. Am Heart J 2007; 154: 1140-5.
49. Amar D, Zhang H, Heerdt PM, Park B, Fleisher M, Thaler HT. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest 2005; 128: 3421-7.
50. Watanabe T, Yasunari K, Nakamura M. Antioxidative actions of statins: potential mechanisms for antiathersclerotic effects. Mini Rev Med Chem 2006; 6: 505-8.